Jessica Schwaber is a Partner and Head of Business Development at weCANdev, a consulting firm specializing in advancing cell and gene therapies from the lab to the clinic and beyond. With extensive wet lab offerings and deep expertise in CRISPR gene editing of iPSCs & T-cells, the weCANdev team has over 50 years of combined experience and has supported more than 10 clinical-stage or marketed products. WeCANdev employs a lean, systematic, and risk-based approach grounded in Quality by Design (QbD) & DoE, regulatory knowledge, and Lean Six Sigma principles, ensuring efficient solutions that directly enhance product quality.
In her role, Jessica spearheads business development initiatives, fostering strategic partnerships and expanding weCANdev's presence in the cell and gene therapy landscape. Her extensive background in the C> field encompasses key roles in preclinical & clinical development, cell editing platform innovation, and the regulatory-compliant, multijurisdictional manufacturing of therapeutic products and editing devices.